Ascendis Pharma A/S (NASDAQ:ASND) Price Target Increased to $196.00 by Analysts at Jefferies Financial Group

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price target increased by Jefferies Financial Group from $174.00 to $196.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. Several other research analysts have also recently issued reports on ASND. StockNews.com upgraded shares […]

Leave a Reply

Your email address will not be published.

Previous post Avinger (NASDAQ:AVGR) Coverage Initiated at StockNews.com
Next post Canaccord Genuity Group Reaffirms Buy Rating for Atara Biotherapeutics (NASDAQ:ATRA)